Innovative Leukemia-On-A-Chip Device Revolutionizes CAR T Therapy Testing
Researchers at NYU have developed the first immunocompetent leukemia-on-a-chip device, transforming how CAR T-cell therapies are tested and personalized, reducing reliance on animal models.
A groundbreaking development by researchers at NYU Tandon School of Engineering has led to the creation of the first immunocompetent leukemia device, which could significantly advance personalized testing for CAR T-cell immunotherapy. This miniature, microscope slide-sized device, known as leukemia-on-a-chip, uniquely replicates both the physical architecture of human bone marrow and the functioning immune system within a laboratory setting. This innovation allows for real-time observation of how immunotherapy drugs interact with cancer cells in an environment that closely mimics the human body, offering a promising alternative to traditional animal testing.
The device recreates three critical regions of bone marrow where leukemia develops: blood vessels, the marrow cavity, and the outer bone lining. When seeded with a patient’s own bone marrow cells, the system self-organizes, producing structural proteins such as collagen, fibronectin, and laminin, which sustain the tissue’s physical and immune complexity. Using advanced imaging, scientists can now watch immune cells patrol the blood vessels, recognize leukemia cells, and eliminate them—an insight that was previously difficult to obtain in live systems.
Moreover, the study revealed that engineered immune cells could activate other immune cells, creating a bystander effect that might influence treatment success and side effects. The research team simulated various clinical scenarios, including complete remission and relapse, and found that next-generation CAR T-cells with enhanced features outperformed standard versions, especially at lower doses.
The leukemia-on-a-chip can be assembled within half a day and supports two-week experiments, drastically reducing the time and complexity compared to animal models that require months of preparation. This technology enables physicians to test a patient’s cancer cells with different therapies before starting treatment, paving the way for more personalized and effective interventions.
The research team also developed a comprehensive index to evaluate various CAR T-cell therapies' performance, providing a detailed prediction of their potential success in actual patients. This innovation aligns with recent FDA initiatives to phase out animal testing in favor of human tissue models, making it highly relevant for future treatment development and safety assessments.
Source: https://medicalxpress.com/news/2025-07-immunocompetent-leukemia-device-car-immunotherapy.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Rising Use of Wegovy Among U.S. Adolescents for Weight Management
The use of Wegovy for weight loss in U.S. teenagers is on the rise, with prescriptions increasing and growing recognition of its potential for managing adolescent obesity, despite ongoing safety evaluations and access limitations.
Advancing Potential Therapies for Age-Related Macular Degeneration
New research uncovers the role of heparan sulfate in trapping lipoproteins that lead to early stages of age-related macular degeneration. Discover promising therapeutic strategies to prevent vision loss.
The Closure of a Historic Clinic Marks a Shift in Access to Late-Stage Abortions in the U.S.
The recent closure of a Colorado-based clinic that provided late-term abortions highlights the decreasing access to vital reproductive healthcare services for women with complex medical needs in the U.S.